Damage related to glucocorticoid treatment ... Additionally, the VDI may not adequately capture the range of damage seen in ANCA-associated vasculitis,14 and may underestimate damage accrued if ...

Avacopan is under clinical development by Amgen and currently in Phase III for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis). According to GlobalData, Phase III drugs ...

According to GlobalData, Phase II drugs for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis ... cold agglutinin disease, unspecified antibody-related neurological diseases, ...

The patient was ultimately diagnosed with ANCA-associated vasculitis (AAV), with a BVAS score of 38 points (general condition ... However, they are suspected to be related to increased retinal ...

Although the management of ANCA-associated vasculitis patients has dramatically improved since the 2000s, strategies to prevent late relapses, decrease glucocorticoid exposure and reduce ...

Avacopan treatment for vasculitis patients shows a significant risk of liver injury, especially in older and low-weight ...

The PEXIVAS trial demonstrated that a reduced-dose glucocorticoid regimen was noninferior to standard dosing in terms of death or end-stage kidney disease in ANCA-associated vasculitis.

Amgen is on pace to return to its pre-Horizon capital structure by the end of 2025. Learn why I upgrade AMGN stock from hold ...

Lupus vasculitis refers to inflammation that affects the blood vessels. What symptoms a person develops will depend on where in the body vasculitis occurs. Lupus vasculitis occurs when the immune ...

Further research is needed to establish if there is a causative link between avacopan and liver injury. A patient with microscopic polyangiitis (MPA)—a form of antineutrophil cytoplasmic antibody ...

Nkarta focuses on autoimmune diseases, with $402.5M in cash. Read why NKTX stock, currently undervalued, offers multiple ...